Blue Cross Blue Shield plans generally do cover Ozempic, but only when it is prescribed for type 2 diabetes and only after prior authorization is approved. Coverage for weight loss is a different story: most BCBS affiliates either exclude it outright or are moving to exclude it. Because Blue Cross Blue Shield is a federation of 33 independent companies, the exact rules depend on which affiliate issues your plan, but the pattern is consistent across the country.1Research file
Diabetes Yes, Weight Loss Usually No
Ozempic is a brand-name injectable containing semaglutide, a GLP-1 receptor agonist. The FDA approved it for managing type 2 diabetes, not weight loss. A sister product from the same manufacturer, Wegovy, uses the same active ingredient at a higher dose and carries the weight-management approval.
That distinction drives almost every coverage decision. BCBS plans routinely approve Ozempic when the prescription is tied to a documented diabetes diagnosis. When Ozempic is prescribed off-label for weight loss, approval is unlikely, and several affiliates have written formal exclusions into their plan documents.
Prior Authorization: What You Have To Document
Almost every BCBS plan requires prior authorization before paying for Ozempic. The specifics vary, but the common building blocks are the same.
A confirmed type 2 diabetes diagnosis. Your provider needs to document the diagnosis with clinical markers: an HbA1c of 6.5% or higher, fasting plasma glucose of 126 mg/dL or above, or other recognized diagnostic criteria.
Step therapy. Most plans require evidence that you have already tried another antidiabetic medication. BCBS of Massachusetts accepts a prior trial of metformin, insulin, a sulfonylurea, an SGLT-2 inhibitor, or a DPP-IV inhibitor, or documentation that you are intolerant to metformin or have a contraindication.
Age minimums. Some affiliates, including BCBS of Massachusetts, limit coverage to patients 18 or older.
No overlapping GLP-1. You cannot already be taking another GLP-1 receptor agonist.
In Massachusetts, an approval lasts 12 months, after which it must be renewed with updated clinical documentation.
Step Therapy Differs by State
BCBS of Michigan requires a trial of a generic or preferred diabetes medication, and its policy explicitly says that a history of only metformin and a GLP-1 does not meet the step therapy criteria. In practice that means you need to have tried a different class of diabetes drug as well.
BCBS of Texas asks that patients have “tried an antidiabetic agent” before GLP-1 approval, without naming metformin specifically as the required first step.
Anthem Blue Cross, which operates in California and other states as a BCBS-affiliated insurer, requires a documented type 2 diabetes diagnosis confirmed through lab values and states plainly that GLP-1 receptor agonists are “not approved” for weight loss.
Weight-Loss Coverage Is Being Pulled
Several large affiliates have moved to formalize the exclusion of GLP-1s used for weight loss.
BCBS of Massachusetts, beginning with plan renewals in January 2026, excludes all GLP-1 indications except type 2 diabetes. Wegovy, Saxenda, and Zepbound are specifically excluded, and the exclusion reaches other FDA-approved uses such as heart disease prevention and sleep apnea treatment. Because this is classified as a benefit exclusion rather than a medical necessity denial, it cannot be appealed. Members are notified roughly 60 days before their renewal date. Employers with more than 100 employees can pay extra to add weight-loss drug coverage back as a rider; smaller employers do not have that option.
BCBS of Arizona began denying new prior authorization requests for members without a type 2 diabetes diagnosis in May 2024 and extended that rule to renewal requests in September 2024. The policy applies to group plans, individual and family plans, Federal Employee Program plans, and Medicare Advantage plans.
BCBS of Vermont, effective January 2026, excludes GLP-1 medications prescribed specifically for weight loss. Members using these drugs for anything other than managing type 2 diabetes or preventing specific cardiovascular events in cases of obesity pay the full cost.
BCBS of Massachusetts cited the economics directly. It spent $200 million on GLP-1 drugs in 2024 and projected that figure would approach $1 billion by 2026 without changes. About 50,000 of its 3 million members were using a GLP-1 as of early 2025, with roughly 2,000 new members starting each month.
What You’ll Pay If You Are Covered
Where Ozempic lands on your plan’s formulary determines your out-of-pocket cost. In BCBS plans that cover Ozempic for diabetes, it typically sits on Tier 2 (preferred brand) or Tier 3. The Federal Employee Program, the nationwide BCBS plan for federal workers, lists Ozempic as a Tier 2 preferred brand drug with prior approval required.
Tier 2 placement generally means a moderate copay or coinsurance rather than the full retail price. BCBS plans in New York classify Ozempic as Tier 2 or Tier 3. Actual costs vary widely: some commercial plans charge a flat copay, while others use coinsurance ranging from 25 to 40 percent of the drug’s cost. For reference, the average retail price for a 30-day supply of Ozempic without insurance is roughly $1,396.
Novo Nordisk offers a manufacturer savings card that can reduce the cost to as little as $25 for up to a three-month prescription, with maximum savings of $100 per month. The card is available to commercially insured patients, including BCBS members, whose plans cover Ozempic, and it remains active for up to 48 months. It is not available to anyone enrolled in Medicare, Medicaid, or TRICARE, and patients whose plans use accumulator adjustment or copay maximizer programs are also ineligible.
For patients paying entirely out of pocket, Novo Nordisk’s self-pay option is $199 for a one-month supply for new patients through June 30, 2026 (limited to the first two fills). Standard self-pay prices are $349 for the 0.25/0.5 mg or 1 mg pen and $499 for the 2 mg pen.
If Your Claim Is Denied
Denial is common. A Washington state report found that semaglutide had the highest volume of prior authorization requests of any prescription drug, with an approval rate of just 47 percent. More than half of initial requests were turned down.
If your BCBS plan denies Ozempic, the appeals process generally runs in three stages.
Internal appeal. File a written appeal within the window stated in the denial letter, typically 60 to 180 days depending on the state and plan. Strengthen the file with lab results showing HbA1c levels, records of failed medication trials with specific dates and dosages, and a medical necessity letter from the prescribing physician.
Peer-to-peer review. Ask your prescribing doctor to speak directly with the insurer’s medical director. A concise summary of your diabetes history, failed treatments, and why alternatives are inappropriate helps the doctor make the case efficiently.
External review. If the internal appeal fails, you can request an independent external review through your state’s insurance department. In California, external reviews through the Department of Managed Health Care are free, and independent physicians make binding decisions, with roughly a 55 percent overturn rate for medical necessity denials. In Michigan, external review decisions can be challenged in circuit court within 60 days of the department’s final order. In New York, members have 180 days to file an internal appeal and can pursue an external appeal through the Department of Financial Services within four months of a final adverse determination, with the independent medical reviewer’s decision binding on the insurer.
One hard limit: appeals do not work against a benefit exclusion. BCBS of Massachusetts has said its 2026 exclusion of weight-loss GLP-1s cannot be appealed or reviewed through formulary exception requests. If the plan document excludes the drug for your indication, no amount of clinical evidence will reverse it; the fight has to be about whether the exclusion applies to your situation, not whether the drug is medically necessary.
A Note on Medicare
If you are on a Medicare plan, including a BCBS-branded Medicare Advantage plan, the rules are stricter. Federal law prohibits Medicare Part D from covering medications used solely for weight loss, and the Trump administration confirmed that restriction in April 2025 by declining to finalize a Biden-era proposed rule that would have treated obesity as a chronic disease eligible for drug coverage. Ozempic itself remains covered under Medicare for its approved diabetes use.
A temporary Medicare GLP-1 Bridge program running from July through December 2026 allows Medicare beneficiaries to access Wegovy and Zepbound for weight reduction at a $50 monthly copayment, with manufacturers providing the drugs at a net price of $245 per month. That bridges into the BALANCE Model, a longer-term Part D initiative launching in January 2027. Separately, semaglutide’s negotiated Medicare price under the Inflation Reduction Act was set at $274 per 30-day supply, effective 2027, and Novo Nordisk has said it plans to lower U.S. list prices for its semaglutide products to about $675 per month starting January 2027.